Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: A randomized controlled trial

Archives of Internal Medicine

Volumn 171, Issue 15, 2011, Pages 1352-1360

  Saito, Toshikazu ^a   Watanabe, Makoto ^e   Nishida, Junko ^a   Izumi, Tomono ^a   Omura, Masao ^a   Takagi, Toshikazu ^b   Fukunaga, Ryuzo ^f   Bandai, Yasutsugu ^a   Tajima, Naoko ^c   Nakamura, Yosikazu ^g   Ito, Masaharu ^d  

^a Social Insurance Chuo General Hospital   (Japan)

^b Ikebukuro Hospital   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d All Japan Federation of Social Insurance Associations   (Japan)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^f Hoshigaoka Employee's Pension Welfare Hospital   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; JAPANESE; LEISURE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WALKING; WORLD HEALTH ORGANIZATION;

EID: 80051626229     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.275     Document Type: Article

References (18)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-1431. (Pubitemid 28405191)
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053. (Pubitemid 38579764)
3. Yang W, Lu J, Weng J, et al China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-1101.
4. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14.
5. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293-301.
6. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537-544.
7. Tuomilehto J, Lindström J, Eriksson JG, et al Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. (Pubitemid 32378388)
8. Knowler WC, Barrett-Connor E, Fowler SE, et al Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. (Pubitemid 34437694)
9. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289-297. (Pubitemid 43185397)
10. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67(2):152-162. (Pubitemid 40093025)
11. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1999.
12. 1c results reported in IFCC units and JDS units [in Japanese]. Rinsho Kagaku. 2008;37(4):393-409.
13. Takahashi K, Yoshimura Y, Kaimoto T, Kunii D, Komatsu T, Yamamoto S. Validation of a food frequency questionnaire based on food groups for estimating individual nutrient intake [in Japanese]. Jpn J Nutr. 2001;59(5):221-232.
14. Yoshimura Y, Takahashi K. Ekuseru-eiyoukun, version 3.0. Tokyo, Japan: Kenpakusha Inc; 2001.
15. 1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-1334.
16. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492-1495.
17. 1c a step forward for diagnosing diabetes? BMJ. 2009;339:b4432. doi:10.1136/bmj. b4432.
18. Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007;7(3):191-199. (Pubitemid 46951916)